A Controlled Trial of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women.
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Atomoxetine (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 26 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.